UNEEG Medical

What UNEEG Medical does

UNEEG Medical A/S is a Danish medtech company founded in 2005 and headquartered in Allerød, Denmark, specializing in subcutaneous EEG monitoring for epilepsy management. The company operates as a subsidiary of T&W Medical A/S, the family holding company of the Tøpholm and Westermann families (founders of Widex), and currently employs approximately 40 people across subsidiaries in Denmark, Germany, the UK, Austria, and the US.

The company's core product is the UNEEG EpiSight System, which comprises four integrated components: a three-electrode subcutaneous EEG implant (UNEEG SubQ), a wireless 24-hour-plus battery recorder (UNEEG EpiSight Recorder), a patient-facing smartphone app for seizure logging and recorder management, and the proprietary AI-powered EpiSight Analyzer software. The system enables continuous EEG recording for up to three years in patients' daily lives, and the Analyzer uses AI to identify suspected seizure activity, correlate seizures with sleep stages, and generate summarized EEG reports. UNEEG has accumulated over 500,000 hours of longitudinal real-world subcutaneous EEG data, which underpins both the analytics platform and its pharmaceutical clinical trial services.

UNEEG generates revenue through four streams: medical device hardware sales (implant and recorder) to healthcare professionals, subscription or license revenue for the EpiSight Analyzer software, professional EEG review services, and drug development partnerships with pharmaceutical companies conducting anti-epileptic and neurodegenerative disease trials. The go-to-market is enterprise field sales targeting epileptologists, neurologists, and epilepsy surgery centers, with named clinical partners including University of Pennsylvania, Mayo Clinic, King's College London, and Universitätsklinik Freiburg. The product received FDA 510(k) clearance and MR Conditional labeling in June 2026, opening the US market following seven years of European commercialization since the 2019 CE mark.

Name

UNEEG Medical

Legal name

UNEEG medical A/S

Website

https://uneeg.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

UNEEG Medical is a Danish medtech company developing a subcutaneous EEG monitoring system for ultra long-term epilepsy management, serving epileptologists, neurology centers, and pharmaceutical drug developers via hardware, AI analytics, and clinical research services.

Ownership category

akta.pro rank

Product category

Neurological Diagnostic and Monitoring Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Subcutaneous EEG monitoring
• Epilepsy medical devices
• Long-term brain monitoring
• AI seizure detection
• Neurological diagnostic devices

Headquarters

HQ city

Allerød

HQ country

Denmark

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Sale of subcutaneous EEG implant (UNEEG SubQ) and wireless recorder (UNEEG EpiSight Recorder) to healthcare providers and patients. Device is implanted by healthcare professionals.
2. Software Analytics Platform: AI-powered EEG analysis software (UNEEG EpiSight Analyzer) provided as a subscription or license to healthcare professionals for seizure detection and sleep analysis.
3. EEG Review Service: Professional EEG reading and interpretation services by trained specialists, supporting pharmaceutical companies in drug development trials.
4. Drug Development Partnership: Collaboration with pharmaceutical companies providing EEG monitoring services for clinical trials of anti-epileptic drugs and neurodegenerative disease treatments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

UNEEG Medical designs, manufactures, and sells the UNEEG EpiSight System, a breakthrough ultra long-term subcutaneous EEG monitoring solution for epilepsy management. The integrated system combines a three-electrode subcutaneous implant, a discreet wireless recorder with 24+ hour battery, a smartphone app, and an AI-powered analytics platform that performs automated seizure detection and sleep correlation analysis on continuous EEG data recorded for up to three years during patients' everyday lives. The company also offers professional EEG review services and ultra long-term monitoring partnerships for pharmaceutical companies conducting anti-epileptic drug clinical trials.

Product overview

UNEEG Medical offers the UNEEG EpiSight System as its primary product offering - a complete ultra long-term subcutaneous EEG monitoring solution for epilepsy management. The system comprises four integrated components: the UNEEG SubQ Implant (a three-electrode subcutaneous EEG measuring device), the UNEEG EpiSight Recorder (discreet wireless hardware with 24+ hour battery), the UNEEG EpiSight App (patient-facing smartphone application), and the UNEEG EpiSight Analyzer (proprietary AI analytics software). The complete solution enables continuous EEG recording for up to 3 years during patients' everyday lives, with AI-powered seizure detection and sleep correlation analysis. UNEEG Medical has collected more than 500,000 hours of longitudinal real-world EEG data. Additional offerings include the UNEEG MyConnect data transmission module for automated patient-to-hospital data transfer.

Differentiator

Problem solved

Functional benefit

Brands

• UNEEG EpiSight System: Breakthrough subcutaneous EEG monitoring solution enabling continuous, wireless EEG recording for years for epilepsy management
• UNEEG EpiSight Analyzer
• UNEEG SubQ
• UNEEG EpiSight Recorder
• UNEEG MyConnect
• 24/7 EEG SubQ

Products and services

• UNEEG EpiSight System Breakthrough integrated solution in epilepsy management enabling continuous subcutaneous EEG recording for up to three years. Comprises the UNEEG SubQ implant, UNEEG EpiSight Recorder, UNEEG EpiSight App, and UNEEG EpiSight Analyzer. Targeted at healthcare professionals (epileptologists, neurologists) and epilepsy surgery centers for objective longitudinal seizure and sleep monitoring in patients with drug-resistant epilepsy.
• UNEEG SubQ Implant A subcutaneous EEG measuring device with three electrodes designed for ultra long-term continuous brain monitoring in patients with epilepsy. Implanted by healthcare professionals and capable of recording for years during patients' everyday lives.

Quantifiable outcome

• Average patient adherence of 20.8 hours/day in real-world home monitoring studies
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core.

• King's College LondoncoreStrategic or Co-development Partner · 1 January 2022Collaboration on observational multicenter cohort study funded by NIHR i4i Challenge Awards (£1.8 million). Study focuses on 24/7 EEG SubQ system evaluation. Jonas Duun-Henriksen was a visiting scientist at King's College London where he established the UNEEG acceptance study in people with epilepsy.
• University of PennsylvaniacoreStrategic or Co-development Partner · 1 January 2021Multicenter key study for US approval of 24/7 EEG SubQ system, conducted as part of FDA regulatory pathway. First US patient enrolled in 2021.
• Mayo CliniccoreStrategic or Co-development Partner · 1 January 2021Multicenter key study for US approval of 24/7 EEG SubQ system, conducted as part of FDA regulatory pathway. First US patient enrolled in 2021.
• Universitätsklinik FreiburgcoreStrategic or Co-development Partner · 1 January 2021Multicenter key study for US approval of 24/7 EEG SubQ system, conducted as part of FDA regulatory pathway.
• Austrian Institute of Technology (AIT)coreTechnology or Integration · 1 January 2019Strategic partnership for CE marking of specialized 2-channel version of AIT's encevis software, which contains a seizure detection algorithm. Integration of AIT's automated analysis capabilities with UNEEG's subcutaneous EEG system.
• T&W Engineering A/ScoreStrategic or Co-development PartnerSister company sharing headquarters in Allerød, Denmark. Part of T&W Medical group. Joint shared services including HR, Finance, IT, and Facility management. Collaborative development relationship with Widex EEG development team.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

Emerging players

• Empatica: Empatica develops wearable sensors and AI for seizure detection (EpiMonitor, FDA-cleared), serving epilepsy patients and neurologists. It is an emerging player in continuous, real-world seizure monitoring that competes for the same end-prescriber and patient population, with a less invasive but likely lower-fidelity signal than UNEEG's SubQ implant.
• Epitel: Epitel develops wearable, wireless EEG sensors (e.g., Epilog) for ambulatory seizure monitoring in epilepsy. It is an emerging player pursuing long-term, outpatient EEG with a less invasive approach, making it a relevant emerging alternative to UNEEG's subcutaneous implant.
• Byteflies: Byteflies builds modular wearable sensor patches and a cloud analytics platform for continuous physiological monitoring, with epilepsy as a key vertical. It is an emerging player in the long-term, real-world EEG/wearable neuro-monitoring space that overlaps with UNEEG's value proposition to pharma and clinicians.
• Spark Biomedical: Spark Biomedical develops wearable neurostimulation and monitoring devices, with relevance in adjacent neurological applications. It represents an emerging player in the broader wearable neuro device space that may expand into continuous long-term EEG monitoring for epilepsy or related indications.

Broad incumbents

• iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch is the most established commercial precedent for ultra-long-term, wearable, AI-analyzed ambulatory monitoring. While in cardiology rather than neurology, the business model of patch-plus-AI service and the clinical positioning of multi-day continuous outpatient monitoring are highly analogous to UNEEG's approach.
• Natus Medical: Natus is a long-established neurodiagnostics equipment vendor (EEG, EMG, sleep) with broad hospital channel coverage. It represents the incumbent EEG infrastructure that UNEEG must displace for ultra-long-term applications, and could enter the subcutaneous long-term segment through R&D or acquisition.
• Compumedics: Compumedics manufactures EEG, sleep, and neurology diagnostic systems used in hospitals and research. It is a broad incumbent in the EEG and sleep-monitoring categories that UNEEG's EpiSight System overlaps with, particularly in the long-term ambulatory and sleep-analysis segments.
• Medtronic: Medtronic is a broad incumbent in implantable neuro devices (DBS, brain monitoring) and a potential competitor or strategic acquirer in the continuous brain monitoring space. Its scale, neurology sales channel, and R&D resources make it a key incumbent that could develop or acquire competing ultra-long-term EEG capability.

Direct peers

• NeuroPace: NeuroPace develops the RNS System, an implanted neurostimulator that continuously monitors brain activity and delivers responsive stimulation for drug-resistant epilepsy. It is the most direct competitor in the implanted continuous EEG space for epilepsy, addressing a similar patient population with a more invasive, therapy-oriented solution.
• Ceribell: Ceribell provides point-of-care EEG and AI-powered seizure detection (Claritrix) for hospital and outpatient neurology settings. It targets a similar clinical use case of rapid, continuous EEG monitoring for seizure detection, albeit using a non-invasive scalp-EEG approach rather than subcutaneous.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/uneegmedical
• YouTubeyoutube.com/@uneegmedical
• Facebookfacebook.com/uneegmedical
• LinkedInlinkedin.com/company/uneeg-medical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UNEEG Medical